Gene therapy biotech Benitec Biopharma files for a $70 million US IPO - (NASDAQ via NewsPoints Desk)

  • Benitec Biopharma filed with the US Securities and Exchange Commission to raise up to $70 million in an initial public offering, as reported in NASDAQ.
  • The company, which is developing gene therapies for hepatitis C based on RNA interference, plans to list on the NASDAQ under the symbol BNTC.
  • No pricing terms were disclosed.

To read more NewsPoints articles, click here.